Climb Bio, Inc. (CLYM)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 6,575 | |||
| General and administrative | 4,102 | |||
| Acquired in-process research and development, related party | - | |||
| Total operating expenses | 10,677 | |||
| Loss from operations | -10,677 | |||
| Interest income | 2,173 | |||
| Foreign currency loss | -162 | |||
| Total other income, net | 2,011 | |||
| Net loss | -8,666 | |||
| Unrealized gain on marketable securities | 32 | |||
| Comprehensive loss | -8,634 | |||
| Net loss per share, basic | -0.13 | |||
| Net loss per share, diluted | -0.13 | |||
| Weighted average number of shares outstanding, basic | 67,585,121 | |||
| Weighted-average number of shares outstanding, diluted | 67,585,121 | |||